Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewTeriflunomide is an inhibitor of dihydroorotate dehydrogenase (Kd = 12 nM; Ki = 179 nM). Inhibits proliferation of mitogen- or cytokine-stimulated lymphoid cells in vitro by inhibiting cell cycle progression from G1 to S. Immunosuppressive agent. Active metabolite of leflunomide.
Teriflunomide is also offered as part of the Tocriscreen 2.0 Max, Tocriscreen Antiviral Library and Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.
M. Wt | 270.21 |
Formula | C12H9F3N2O2 |
Storage | Store at +4°C |
Purity | ≥99% (HPLC) |
CAS Number | 108605-62-5 |
PubChem ID | 54684141 |
InChI Key | UTNUDOFZCWSZMS-YFHOEESVSA-N |
Smiles | O=C(/C(C#N)=C(O)/C)NC1=CC=C(C(F)(F)F)C=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 27.02 | 100 |
The following data is based on the product molecular weight 270.21. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 3.7 mL | 18.5 mL | 37.01 mL |
5 mM | 0.74 mL | 3.7 mL | 7.4 mL |
10 mM | 0.37 mL | 1.85 mL | 3.7 mL |
50 mM | 0.07 mL | 0.37 mL | 0.74 mL |
References are publications that support the biological activity of the product.
Williamson et al (1995) Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J.Biol.Chem. 270 22467 PMID: 7673235
Davis et al (1996) The immunosuppressive metabolite of leflun. is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35 1270 PMID: 8573583
Iglesias-Bregna et al (2013) Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the dark agouti rat model of experimental autoimmune encephalomyelitis. J.Pharmacol.Exp.Ther. 347 203 PMID: 23892570
If you know of a relevant reference for Teriflunomide, please let us know.
Keywords: Teriflunomide, Teriflunomide supplier, Active, metabolite, leflunomide, A771726, A, 77-1726, 771226, A77, 1726, dihydroorolate, dehydrogenase, inhibitors, inhibits, immunosuppressive, agent, drug, immunomodulatory, Immunosuppressants, Dihyroorotate, Dehydrogenase, DNA,, RNA, and, Protein, Synthesis, 5069, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for Teriflunomide include:
Takashi et al (2022) Disrupted neural correlates of anesthesia and sleep reveal early circuit dysfunctions in Alzheimer models. Cell Rep 38 110268 PMID: 35045289
Styr et al (2019) Mitochondrial Regulation of the Hippocampal Firing Rate Set Point and Seizure Susceptibility. Neuron 102 1009 PMID: 31047779
Do you know of a great paper that uses Teriflunomide from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Teriflunomide and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.